Alterations in ER homeostasis have been implicated in the pathophysiology of obesity and type-2 diabetes (T2D). Acute ER stress induction in the hypothalamus produces glucose metabolism perturbations. However, the neurobiological basis linking hypothalamic ER stress with abnormal glucose metabolism remains unknown. Here, we report that genetic and induced models of hypothalamic ER stress are associated with alterations in systemic glucose homeostasis due to increased gluconeogenesis (GNG) independent of body weight changes. Defective alpha melanocyte-stimulating hormone (a-MSH) production underlies this metabolic phenotype, as pharmacological strategies aimed at rescuing hypothalamic a-MSH content reversed this phenotype at metabolic and molecular level. Collectively, our results posit defective a-MSH processing as a fundamental mediator of enhanced GNG in the context of hypothalamic ER stress and establish a-MSH deficiency in proopiomelanocortin (POMC) neurons as a potential contributor to the pathophysiology of T2D.
INTRODUCTION
Perturbations in ER performance, and the subsequent development of ER stress, have been implicated in the pathophysiology of metabolic disorders such as obesity and type-2 diabetes (T2D) (Ozcan et al., 2004 (Ozcan et al., , 2006 . In particular, the hypothalamus has emerged as a key area of the CNS, causally linking ER stress, leptin resistance, and overweight (Cakir et al., 2013; Contreras et al., 2014; Hosoi et al., 2008; Ozcan et al., 2009; Won et al., 2009; Zhang et al., 2008) . We have recently reported that the cellular responses to ER stress are modulated by Mitofusin 2 (Mfn2) (Muñ oz et al., 2013; Schneeberger et al., 2013; Sebastiá n et al., 2012) , a GTPase-containing mitochondrial protein that plays a prominent role in establishing mitochondria-ER contacts (de Brito and Scorrano, 2008) . Consistently, mice lacking Mfn2 in hypothalamic proopiomelanocortin (POMC) neurons (POMCMfn2KO), a subpopulation of anorexigenic neurons critical for energy and glucose homeostasis regulation (Grayson et al., 2013; Schneeberger et al., 2014) , exhibited an obesogenic phenotype due to early ER-stress-induced leptin resistance (Schneeberger et al., 2013) .
Albeit the connection between hypothalamic ER stress and obesity is well established, its potential contribution to the development of glucose homeostasis alterations irrespective of body weight has been scarcely investigated. Pharmacological and genetic studies indicate that ER stress pathways in the hypothalamus, and in POMC neurons, regulate whole-body glucose metabolism (Purkayastha et al., 2011; Williams et al., 2014) . However, the precise molecular downstream mediators remain undefined.
Here, we explored the mechanisms by which hypothalamic POMC neurons, in the context of ER stress, contribute to systemic glucose metabolism disturbances. To this aim, we studied genetic and induced mouse models that develop early hypothalamic ER stress. Our results establish alpha-melanocyte-stimulating hormone (a-MSH), a neuropeptide derived from POMC processing, as a key mediator of hypothalamic ER-stress-induced hepatic gluconeogenesis (GNG) independent of obesity.
RESULTS

Deletion of Mfn2 in POMC Neurons Leads to Systemic Alterations in Glucose Homeostasis Independently of Obesity Development
Twelve-week-old POMCMfn2KO mice exhibit a dramatic obese phenotype caused by hyperphagia and reduced thermogenesis.
As expected, these mice showed marked alterations in glucose homeostasis including hyperglycemia, hyperinsulinemia, glucose intolerance, and insulin resistance (Schneeberger et al., 2013; Figures S1A-S1D) .
To discriminate whether abnormal glucose homeostasis was a primary defect or secondary to obesity, we performed subsequent studies in 6-week-old POMCMfn2KO mice when no differences in body weight or adiposity were recorded (Schneeberger et al., 2013) . Weight-matched POMCMfn2KO mice exhibited fasting hyperglycemia ( Figure 1A ), glucose intolerance (Figure 1B) , and insulin resistance ( Figure 1C) . Together, these results demonstrate defective glucose control in POMCMfn2KO mice irrespective of body weight.
Increased Hepatic Glucose Production in Young
Weight-Matched POMCMfn2KO Mice Pancreatic b-cell dysfunction may cause abnormal glucose homeostasis. However, no alterations in plasma insulin ( Figure 1D ), glucose-stimulated insulin secretion (GSIS) ( Figure 1E ), pancreatic islet architecture, and number (control: 46 ± 9 islets/cm 2 versus POMCMfn2KO: 60 ± 6 islets/cm 2 ; NS; n = 3/genotype) or pancreatic a/b-cell mass ( Figures 1F and 1G ) were observed in 6-week-old weight-matched POMCMfn2KO mice, indicating normal pancreatic islet mass and function.
To assess the contribution of individual insulin-sensitive tissues to the development of glucose metabolism perturbations in POMCMfn2KO mice, we measured in vivo glucose uptake (A-C) Fed and fasted glycemia (A), glucose tolerance (B), and insulin sensitivity (C) tests in control (n = 9-10) and POMCMfn2KO (n = 7-9) mice. (D and E) Plasma insulin (D) and in vivo GSIS (E) in control (n = 10) and POMCMfn2KO (n = 7) mice. (F and G) Pancreatic beta/alpha cell mass (F) and representative fluorescence images (G) of pancreatic islets (n = 3/genotype). (H) Tissue-specific glucose uptake in soleus muscle (Sol), gastrocnemius muscle (Gas), liver (Liv), and epididymal white adipose tissue (eWAT) in control (n = 3) and POMCMfn2KO (n = 4) mice. Data are expressed as mean ± SEM. **p < 0.01. NS, not significant. The scale bar represents 50 mm. See also Figure S1 . following a glucose load. 2-[ 3 H]deoxyglucose (2DG) uptake in POMCMfn2KO mice was similar to control counterparts in all tested tissues, although a non-significant trend to exhibit higher values in skeletal muscle was observed in mutant mice ( Figure 1H ). Nevertheless, this observation could not explain the impaired glucose homeostasis observed in POMCMfn2KO mice and it could represent a secondary compensatory mechanism.
The liver is a major regulator of whole-body glucose homeostasis through hepatic glucose production (HGP). Pyruvate tolerance test (PTT) and glycerol tolerance tests (GlyTTs) were used to assess HGP due to the difficulty to perform hyperinsulinemic-euglycemic clamps at such a young age (4 weeks). POMCMfn2KO mice displayed significantly higher blood glucose levels (Figures 2A-2D ), suggestive of enhanced HGP. 
(legend continued on next page)
In an attempt to determine the hepatic molecular alterations leading to enhanced GNG, we performed a global transcriptomic analysis in livers from young weight-matched POMCMfn2KO and control mice (Table S1 ). To establish relevant dysregulated pathways, we conducted associated disease analyses. The most highly enriched category was ''nutritional and metabolic diseases,'' with 535 transcripts significantly altered ( Figure S2A ; Table S2 ). A large proportion of these transcripts (62%) belonged to the subcategory ''glucose metabolism disorders'' ( Figure S2B ). Consistent with enhanced HGP, the expression of key hepatic gluconeogenic genes such as cAMP responsive element-binding protein 1 (Creb1), glucose 6-phosphatase (G6pc), and cytosolic phosphoenolpyruvate carboxykinase (Pck1) was increased in mutant mice ( Figure 2E ; Table S2 ). Overexpression of these genes was validated by qRT-PCR ( Figure S2C ). Hepatic phosphoenolpyruvate carboxykinase (PEPCK) enzyme activity was also increased in POMCMfn2KO mice ( Figure 2F ). No changes in liver glycogen content were observed (control: 2.85 ± 0.97 mg/mg liver versus POMCMfn2KO: 3.34 ± 0.76 mg/mg liver; NS; n = 15/genotype). These results suggest that enhanced GNG is a major contributor to altered glucose homeostasis in weightmatched POMCMfn2KO mice.
In contrast, hepatic lipid metabolism was unperturbed in mutant mice, as no changes in plasma triglycerides ( Figure 2G ), liver weight ( Figure 2H ), hepatic triglyceride concentration ( Figure 2I ), and expression of key enzymes such as acetyl-CoA carboxylase (Acaca), fatty acid synthase (Fasn), diacylglycerol acyltransferase 2 (Dgat2), stearoyl-coenzyme A desaturase 1 (Scd1), or carnitine palmitoyltransferase 1 (Cpt1a) were observed ( Figure 2J ).
Next, we assessed biological parameters of hypothalamic-pituitary-adrenal axis function. Plasma concentration of epinephrine (control: 23.6 ± 1.2 pg/ml versus POMCMfn2KO: 27.1 ± 2.7 pg/ml; NS; n = 5-7/genotype), norepinephrine (control: 235 ± 50 pg/ml versus POMCMfn2KO: 280 ± 47 pg/ml; NS; n = 5-7/genotype), adenocorticotropic hormone (control: 48.8 ± 7.1 pg/ml versus POMCMfn2KO: 76.3 ± 19.3 pg/ml; NS; n = 5-7/genotype), and corticosterone (basal control: 48.2 ± 12.3 pg/ml versus basal POMCMfn2KO: 68.3 ± 21.2 pg/ml; NS; n = 6-9/genotype; stressed control: 447 ± 25 pg/ml versus stressed POMCMfn2KO: 451 ± 35 pg/ml; NS; n = 6-9/genotype) was unaltered. Together, these results suggest that neither defective insulin counter-regulatory hormones nor hypothalamic-pituitary-adrenal axis function mediates the enhanced GNG observed in POMCMfn2KO mice.
Reduced a-MSH in POMCMfn2KO Mice Underlies Enhanced GNG Hypothalamic POMC neurons release a-MSH, a critical neuropeptide implicated in energy balance and metabolic control (Schneeberger et al., 2014) . Weight-matched 6-week-old POMCMfn2KO mice displayed decreased hypothalamic a-MSH content (Schneeberger et al., 2013) and staining in neuronal projections to target areas such as the paraventricular nucleus (PVN) ( Figure 3A ). To investigate whether augmented GNG resulted from reduced a-MSH production, we assessed the effects of intracerebroventricular (i.c.v.) administration of this peptide. Acute i.c.v. a-MSH delivery to POMCMfn2KO mice normalized GNG ( Figures 3B and 3C) . Consistently, expression of hepatic gluconeogenic enzymes Pck1 and G6pc ( Figure 3D ), as well as PEPCK activity ( Figure 3E ), was restored after central a-MSH administration.
The Effects of a-MSH on HGP in POMCMfn2KO Mice Are Mediated by CREB Transcriptome analysis identified Creb1 as a differentially expressed gene in livers from POMCMfn2KO mice (Figures 2E and S2C) . Key gluconeogenic genes, including Pck1 and G6pc, contain cAMP responsive elements (CRE) (Altarejos and Montminy, 2011) , and thus, we assessed whether Creb1 mediated the effects of hypothalamic a-MSH on GNG. Consistent with transcriptomic data, liver homogenates from weightmatched 6-week-old POMCMfn2KO mice showed increased CREB protein content, which was unchanged after i.c.v. a-MSH administration ( Figures 3F and 3G ). CREB activity is mainly regulated by phosphorylation (Altarejos and Montminy, 2011) . Liver phospho-CREB (pCREB) levels in POMCMfn2KO were also elevated ( Figures 3F and 3G) . Remarkably, acute i.c.v. a-MSH was able to normalize pCREB levels to control values ( Figures 3F and 3G) . To assess the relevance of these findings, we investigated the effects of the manipulation of CREB phosphorylation status using the PKA selective inhibitor Rp-cAMPS, which effectively inhibits GNG (Dragland-Meserve et al., 1986) . POMCMfn2KO mice treated with Rp-cAMPS displayed a normalized PTT, consistent with reduced gluconeogenic capacity ( Figure S3 ). Together, these results indicate that a-MSH deficiency in POMCMfn2KO mice leads to enhanced gluconeogenic programming mediated by CREB.
ER-Stress-Associated Reduction of a-MSH Is the Cause of Enhanced HGP in POMCMfn2KO Mice
Decreased a-MSH content, in the context of hypothalamic ER stress, is normalized after ER stress relief by central chaperone treatment (Cakir et al., 2013; Schneeberger et al., 2013) . Thus, we evaluated the acute effects of i.c.v. delivery of the chemical chaperone tauroursodeoxycholic acid (TUDCA) on GNG in POMCMfn2KO mice. This treatment was able to normalize hypothalamic a-MSH content ( Figure 3H ) and ameliorated the gluconeogenic response to pyruvate in POMCMfn2KO mice (Figures 3I and 3J). Hepatic expression of gluconeogenic genes was also recovered after TUDCA administration ( Figure 3K ). Collectively, our data suggest that augmented GNG in POMCMfn2KO mice is the consequence of ER-stress-driven reduction of hypothalamic a-MSH levels.
Short-Term HFD Administration Causes ER-StressMediated Reduction of Hypothalamic a-MSH Content and Enhanced HGP in the Absence of Obesity The relevance of hypothalamic a-MSH in the regulation of GNG was further investigated in a pathophysiological model that recapitulates the effects of Western diets upon glucose homeostasis. To this end, we fed C57Bl/6J mice with high-fat diet for 4 consecutive days (4d-HFD), a sufficiently brief time interval to avoid weight gain as a possible confounding factor. Consistent with previous reports Wang et al., 2001; Wiedemann et al., 2013 ), short-term HFD feeding caused no significant changes in body weight ( Figure 4A ) or plasma leptin levels ( Figure 4B ) but induced fasting hyperglycemia ( Figure 4C ), hyperinsulinemia ( Figure 4D ), and impaired pyruvate tolerance ( Figure 4E ) when compared to counterparts fed with normal chow diet (NCD). Consistently, increased expression of liver gluconeogenic genes ( Figure 4F ) and PEPCK activity ( Figure 4G ) were observed in 4d-HFD mice.
The molecular mechanisms underlying these rapid detrimental effects on glucose homeostasis after short-term HFD feeding are incompletely understood. We explored whether 4d-HFD regime was sufficient to enable ER stress in the hypothalamus of C57Bl/6J mice. We found that 4d-HFD feeding significantly increased the transcript expression of key ER stress markers, such as activating transcription factor 4 (Atf4) and 6 (Atf6), spliced form of X-box-binding protein 1 (Xbp1s), and binding immunoglobulin protein (BiP/Hspa5), suggesting enhanced hypothalamic ER stress ( Figure 4H ). Protein expression analysis of ER stress mediators in the hypothalamus from 4d-HFD mice also showed a significant increase of PERK phosphorylation ( Figure 4I ), which is a major transducer of the ER stress response in the hypothalamus (Ozcan et al., 2009) , and a trend to increase in other ER stress markers ( Figure S4A ). Mfn2 expression was reduced in the hypothalamus of 4d-HFD ( Figure 4J ). Remarkably, the deleterious effects of short-term HFD were associated with reduced hypothalamic a-MSH content ( Figure 4K ) and fiber staining in neuronal projections to the PVN ( Figure 4L ) despite unaltered Pomc mRNA (NCD: 100% ± 13% versus 4d-HFD: 97% ± 12%; NS; n = 7/group), POMC protein content ( Figure 4M ), or POMC neuron number (NCD: 983 ± 40 versus 4d-HFD: 993 ± 76; NS; n = 3/group). The reduced a-MSH/ POMC ratio suggests defective POMC processing. However, no changes in the transcript expression of the main POMC convertases were observed in the hypothalamus of 4d-HFD mice ( Figure S4B ). Given that proconvertase (PC) 1/3 and PC2 are regulated at protein level rather than mRNA level (Cakir et al., 2013) , we conducted immunoblot analysis. Whereas PC1/3 expression was unchanged, PC2 levels were increased in the hypothalami from 4d-HFD mice ( Figure S4C ), likely as a compensatory mechanism to maintain adequate melanocortin tone.
To demonstrate a causal relationship between defective hypothalamic a-MSH levels and increased GNG, we conducted i.c.v. a-MSH administration studies. Acute delivery of a-MSH was able to restore pyruvate tolerance in 4d-HFD mice ( Figure 4N ).
DISCUSSION
Enhanced hepatic GNG is a major contributor of fasting hyperglycemia in T2D patients (DeFronzo et al., 1989; Magnusson et al., 1992) . In addition to the classical hormonal regulatory mechanisms, the brain has long been recognized as a key regulator of this biological process (Bisschop et al., 2015) and hypothalamic POMC neurons have recently emerged as a relevant neuronal population implicated in the regulation of HGP (Berglund et al., 2012 (Berglund et al., , 2013 Claret et al., 2011; Shi et al., 2013; Williams et al., 2014; Xu et al., 2010) . Given that acute ER stress induction in the hypothalamus produces glucose metabolism alterations in a body-weight-independent manner (Purkayastha et al., 2011) , we investigated the molecular link between ER stress in POMC neurons and glucose homeostasis.
We have recently reported that Mfn2 critically modulates cellular ER stress responses (Muñ oz et al., 2013) . Consistently, deletion of Mfn2 leads to ER stress in vitro and in vivo (Ngoh et al., 2012; Schneeberger et al., 2013; Sebastiá n et al., 2012) . In POMC neurons, Mfn2 deficiency causes an obesogenic phenotype characterized by early hypothalamic ER-stress-induced leptin resistance (Schneeberger et al., 2013) . Remarkably, POMCMfn2KO mice exhibit abnormal glucose homeostasis before the onset of obesity due to enhanced GNG. Along the same lines, our short-term HFD model recapitulated the phenotypical outcome of POMCMfn2KO mice, defined by reduced hypothalamic Mfn2 expression, ER stress, and enhanced gluconeogenic capacity in the absence of changes in body weight.
Defective processing and production of a-MSH neuropeptide has been proposed to constitute the underlying neurobiological basis of hypothalamic ER stress in obesity (Cakir et al., 2013; Schneeberger et al., 2013) . Similarly, 4 days of HFD administration also caused a reduction in hypothalamic a-MSH content and fiber staining in the PVN. Even though abnormal a-MSH trafficking to target areas cannot be completely ruled out, the reduced a-MSH/POMC ratio suggests that defective POMC processing is the likeliest cause in both models studied. Our data also indicate that processing perturbations are the consequence of intrinsic factors (e.g., POMC protein misfolding) rather than defective PC expression.
In view of these results, it was reasonable to speculate that altered a-MSH content was also implicated in the development of inadequate glucose homeostasis in the context of hypothalamic ER stress. Indeed, our data demonstrate a causative involvement of a-MSH in the maintenance of systemic glucose homeostasis, as restoration of hypothalamic a-MSH levels, either by direct administration of this peptide and/or pharmacological ER stress relief, normalized HGP in these mouse models. The beneficial effects of the pharmacological treatment are likely mediated through direct actions on POMC neurons, although we cannot exclude potential effects on other hypothalamic areas due to the delivery route used.
The precise mechanisms by which hypothalamic a-MSH controls hepatic GNG are still incompletely understood, although a key mediator appears to be the modulation of CREB activity in the liver. CREB is considered a master positive regulator of gluconeogenic gene expression (Altarejos and Montminy, 2011; Erion et al., 2009; Herzig et al., 2001 Herzig et al., , 2003 . However, conditional genetic ablation of Creb1 in adult hepatocytes did not cause alterations in glucose metabolism or expression of gluconeogenic genes . This suggests functional redundancy, and thus we cannot exclude modulatory effects of a-MSH on other proteins that bind to CREs.
Extensive evidence indicates that the hypothalamus, and particularly the melanocortin system, regulates HGP through multisynaptic connections to autonomic centers (Bisschop et al., 2015) . Recent studies have used genetic deletion and reexpression strategies to delineate the role of melanocortin signaling in sympathetic and parasympathetic preganglionic neurons Rossi et al., 2011) . Reactivation of melanocortin 4 receptors (MCR4s), which bind a-MSH, in all cholinergic neurons attenuated hyperglycemia and hyperinsulinemia, whereas its selective re-expression in brainstem neurons was sufficient to improve hyperinsulinemia (Rossi et al., 2011) . This suggests that MC4R signaling in cholinergic preganglionic sympathetic neurons mediates HGP suppression. This is consistent with our data demonstrating that reduced melanocortin tone in POMCMfn2KO or short-term HFD-fed mice is associated with increased GNG. The importance of the sympathetic outflow on the hypothalamic regulation of HGP is further supported by other studies (Purkayastha et al., 2011; van den Hoek et al., 2008) . In this sense, preliminary results showed that prazosin (an alpha-1 adrenergic receptor blocker) was able to reverse enhanced HGP in POMCMfn2KO mice (M.S., A.G.G.-V., and M.C., unpublished data). Thus, it is tempting to speculate that a-MSH actions are mediated by sympathetic innervation, although the precise mechanisms by which POMC neurons propagate this signal remain unknown.
In summary, here we demonstrate that pathophysiological situations associated with hypothalamic ER stress cause systemic glucose homeostasis perturbations, named enhanced GNG, in the absence of obesity. We provide evidence that deficient a-MSH output, which is exclusively released by POMC neurons, is a critical mediator of hypothalamic ER-stress-induced GNG. These results provide further understanding of the central mechanisms involved in HGP regulation and establish a-MSH processing defects in POMC neurons as a potential contributor to the pathophysiology of T2D.
EXPERIMENTAL PROCEDURES
Mice and Diets C57BL/6J mice were purchased from Harlan Europe. The generation of POMCMfn2KO mice has been previously reported (Schneeberger et al., 2013) . Mice were maintained on a 12:12 hr light-dark cycle with free access to water and NCD (Harlan Research Laboratories) or HFD (45% kcal fat; Research Diets) for 4 days (starting at 6 weeks of age). POMCMfn2KO male mice were studied at 5 to 6 weeks of age or otherwise stated. In vivo studies were performed with approval of the University of Barcelona Ethics Committee, complying with current Spanish and European legislation.
Physiological Measurements
Blood samples were collected via tail vein or trunk bleeds using a capillary collection system (Sarstedt). Blood glucose was measured using a Glucometer (Arkray). GTT (D-glucose; 2 g/kg), GSIS (D-glucose; 3 g/kg), PTT (sodium pyruvate; 1 g/kg), and GlyTT (glycerol; 1 g/kg) were performed on overnight fasted mice. Insulin sensitivity tests (0.4 IU/kg) were performed on 6 hr fooddeprived mice. All compounds were i.p. injected and blood glucose determined at the indicated time points. Plasma hormones were measured by commercially available ELISA kits in overnight fasted mice: insulin (Crystalchem); leptin (Crystalchem); epinephrine and norepinephrine (Labor Diagnostika Nord); adrenocorticotropic hormone (Abnova); and corticosterone (Immuno Diagnostic Systems). Plasma triglycerides were measured using quantitative enzymatic determination TAG kit (Sigma-Aldrich).
Hypothalamic POMC, a-MSH Content, and Immunohistochemistry Mice were transcardially perfused with 4% paraformaldehyde, overnight fixed, cryoprotected in 30% sucrose, and frozen. Brains were cut into 25-mm-thick slices using a sliding microtome. Hypothalamic slices were extensively washed in KPBS buffer and blocked in 2% donkey serum in KPBS plus 0.4% Triton X-100. Sections were incubated with a-MSH antibody (1:20,000; Chemicon) or POMC antibody (1:1,000; Phoenix Pharmaceuticals) in blocking buffer for 48 hr at 4 C. After washing with KPBS, slices were incubated with the appropriate Alexa 488 antibody (1:400; Molecular Probes).
Imaging was performed using a Leica DMI 6000B microscope. a-MSH integrated density after image skeletonization was calculated using ImageJ software. POMC neurons were counted in equivalent ARC sections (bregma À1.46 to À1.94). For a-MSH content, hypothalami were sonicated in 500 ml of 0.1 N HCl solution. Lysates were centrifuged and supernatants used for the quantification of a-MSH by ELISA (Phoenix Pharmaceuticals). Protein concentration was determined by Bradford.
qRT-PCR Hypothalami and livers were harvested and immediately frozen in liquid nitrogen. mRNA was isolated using Trizol. Retrotranscription and qRT-PCR was performed as previously described (Claret et al., 2011) . Transcript levels were measured using the ABI Prism 7900 HT system (Applied Biosystems). Proprietary Taqman Gene Expression assay FAM/TAMRA primers used (Applied Biosystems) were Acaca (Mm01304277_m1),
, and Xbp1s (Mm03464496_m1).
Western Blot Analysis
Protein lysates were prepared from pulverized whole-liver samples or mediobasal hypothalamic microdissections in RIPA buffer (Sigma-Aldrich) supplemented with protease and phosphatase inhibitors. Cleared supernatants were resolved on pre-cast gradient 4%-12% SDS-PAGE gels (Bio-Rad), transferred onto PVDF membranes (Millipore), and probed with the following primary antibodies: phospho CREB (Ser133; 1:1,000; Cell Signaling Technology); CREB (1:1,000; Cell Signal); Mfn2 (1:1,000; Abcam); phospho PERK (1:1,000; Cell Signaling); PERK (1:1,000; Cell Signal); XBP1 (1:1,000; Abcam); p-eiF2a (1:1,000; Cell Signal); ATF4 (1:1,000; Aviva Systems Biology), ATF6
(1:1,000; Santa Cruz Biotechnology); CHOP (1:1,000; Santa Cruz); PC1 (1:5,000; MyBiosource); PC2 (1:5,000; MyBiosource), alpha-tubulin (1:8,000; Sigma-Aldrich); and beta-actin (1:5,000; Sigma-Aldrich). Detection was performed by enhanced chemiluminescence (Pierce). Band intensities were quantified using the ImageJ software.
i.c.v. Cannulation and Treatments i.c.v. surgery was performed at 9 weeks of age as previously described (Schneeberger et al., 2013) . On experimental days, 10-week-old control and POMCMfn2KO mice or C57BL/6J mice fed with NCD or HFD for 4 days were fasted overnight and infused with 2 ml of either vehicle (aCSF; Tocris Bioscience), a-MSH (1 nmol/ml; Sigma-Aldrich), or TUDCA (2.5 mg/ml; Calbiochem) just after lights on. Two hours later, a PTT was performed. For TUDCA experiments, an extra i.c.v. injection was performed just before fasting.
Statistics
Data are expressed as mean ± SEM. p values were calculated using unpaired Student's t test, two-way ANOVA, or one-way ANOVA with post hoc Sidak multiple comparisons test as appropriate. p < 0.05 was considered significant.
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